Blood and Tissue Study of Patients in NIH Protocol 08-C-0800
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 2 - 99 |
| Updated: | 4/6/2019 |
| Start Date: | December 9, 2008 |
| End Date: | May 18, 2017 |
A Group Wide Biology and Banking Study for Phase II Study of R1507
Background:
- This study is a companion biology study to NIH protocol 08-C-0080, A Phase II Trial of
R1507, a Recombinant Human Antibody to the Insulin-Like Growth Factor-1 Receptor for the
Treatment of Patients with Recurrent or Refractory Ewing s Sarcoma, Osteosarcoma,
Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
- Analysis of tumor tissue and blood samples from patients with sarcomas who are receiving
treatment with the experimental drug R1507 may help elucidate the biology of sarcomas
and how they respond to certain therapies with monoclonal antibodies.
Objectives:
- To study the effect over time of R1507 on the proteins and cells in the blood and tissue
of patients with sarcoma in order to learn more about how patients respond to the
treatment and what changes occur in their cells.
- To discover possible new treatments for cancer.
Eligibility:
- Participants in NIH protocol 08-C-0080 for the study of R1507 to treat people with
various sarcomas.
Design:
- Patients who previously agreed as part of protocol 08-C-0800 to have blood sampling for
pharmacodynamic studies (blood draws to test blood for levels of R1507 and how the body
affects R1507) will not have any additional blood drawn as part of this study.
- Patients who did not previously agree to pharmacodynamic sampling as part of the
protocol 08-C-0800 will be asked to give 6 blood samples at various time periods during
the study.
- Pathology slides or tissue blocks obtained under protocol 08-C-0800 will be forwarded to
F. Hoffmann-La Roche laboratories for analysis.
- This study is a companion biology study to NIH protocol 08-C-0080, A Phase II Trial of
R1507, a Recombinant Human Antibody to the Insulin-Like Growth Factor-1 Receptor for the
Treatment of Patients with Recurrent or Refractory Ewing s Sarcoma, Osteosarcoma,
Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
- Analysis of tumor tissue and blood samples from patients with sarcomas who are receiving
treatment with the experimental drug R1507 may help elucidate the biology of sarcomas
and how they respond to certain therapies with monoclonal antibodies.
Objectives:
- To study the effect over time of R1507 on the proteins and cells in the blood and tissue
of patients with sarcoma in order to learn more about how patients respond to the
treatment and what changes occur in their cells.
- To discover possible new treatments for cancer.
Eligibility:
- Participants in NIH protocol 08-C-0080 for the study of R1507 to treat people with
various sarcomas.
Design:
- Patients who previously agreed as part of protocol 08-C-0800 to have blood sampling for
pharmacodynamic studies (blood draws to test blood for levels of R1507 and how the body
affects R1507) will not have any additional blood drawn as part of this study.
- Patients who did not previously agree to pharmacodynamic sampling as part of the
protocol 08-C-0800 will be asked to give 6 blood samples at various time periods during
the study.
- Pathology slides or tissue blocks obtained under protocol 08-C-0800 will be forwarded to
F. Hoffmann-La Roche laboratories for analysis.
Background:
- R1507 is a recombinant, fully human monoclonal IgG1 antibody that binds specifically to
the human IGF-1R, resulting in direct inhibition of ligand binding and loss of receptor
protein on the cell surface following intracellular internalization and degradation.
- Binding of R1507 has been shown to inhibit signal transduction and proliferation and
survival functions mediated by the IGF-1R in cancer cells. Pre-clinical toxicology and
safety pharmacology studies have been performed with R1507 and phase 1 studies in adults
have resulted in a recommended intravenous dose of 9 mg/kg weekly. Phase 1 studies are
ongoing in children.
- A Phase II study (SARC011/Roche NO21157): A Phase II Trial of R1507, a Recombinant Human
Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with
recurrent or refractory Ewing s sarcoma, osteosarcoma, synovial sarcoma,
rhabdomyosarcoma and other sarcomas will allow an opportunity to collect tumor tissue
and serum samples to further characterize the biology of sarcomas and their response to
IGF1-R monoclonal antibody therapy.
Objectives:
- To analyze tumor tissue for IGF-1R, phosphor (p)-IGF-1R, Akt, p-Akt, PTEN, and other
candidate markers related to the mechanism of action of R1507 in the treatment of
patients with sarcoma and other solid tumors.
- To determine whether specific tissue-based assays performed on diagnostic specimens will
allow for the identification of newer prognostic categories and potentially new
molecular targets for treatment of patients with sarcoma and other solid tumors.
- To determine whether serum levels of free IGF-I/II, total IGF-I and shed IGF-1R are of
significance in the outcome of patients with sarcoma and other solid tumors.
- To identify new treatment targets for therapy. Further testing of these potential
targets will be carried out in hopes of expediting translation of these findings to the
clinical setting.
Eligibility:
-All patients enrolled on the Phase II study SARC011/Roche NO21157 will be eligible for
enrollment.
Design:
- Unstained tumor tissue slides from samples sent for confirmatory diagnosis will be
forwarded for further analysis from Central Pathology Labs in New York or Leiden to
Roche Clinical Sample Operations (CSO). Tissue based assays to evaluate the status of
IGF-1R downstream pathway will be performed by Roche Central Lab (HistoGeneX) and NCI
Lab.
- Serum based assays of free serum IGF-I/II, total serum IGF-I and shed IGF-1R receptor
will be run using the samples obtained prior to the first dose of R1507 and at specified
times during treatment as described in Table 3.3. All serum samples will be shipped to
the Roche CSO and forwarded for analysis to the designated laboratories. Serum based
assays will be performed by Roche Central Lab (MicroCoat) and Roche Diagnostics
(Penzberg).
- R1507 is a recombinant, fully human monoclonal IgG1 antibody that binds specifically to
the human IGF-1R, resulting in direct inhibition of ligand binding and loss of receptor
protein on the cell surface following intracellular internalization and degradation.
- Binding of R1507 has been shown to inhibit signal transduction and proliferation and
survival functions mediated by the IGF-1R in cancer cells. Pre-clinical toxicology and
safety pharmacology studies have been performed with R1507 and phase 1 studies in adults
have resulted in a recommended intravenous dose of 9 mg/kg weekly. Phase 1 studies are
ongoing in children.
- A Phase II study (SARC011/Roche NO21157): A Phase II Trial of R1507, a Recombinant Human
Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with
recurrent or refractory Ewing s sarcoma, osteosarcoma, synovial sarcoma,
rhabdomyosarcoma and other sarcomas will allow an opportunity to collect tumor tissue
and serum samples to further characterize the biology of sarcomas and their response to
IGF1-R monoclonal antibody therapy.
Objectives:
- To analyze tumor tissue for IGF-1R, phosphor (p)-IGF-1R, Akt, p-Akt, PTEN, and other
candidate markers related to the mechanism of action of R1507 in the treatment of
patients with sarcoma and other solid tumors.
- To determine whether specific tissue-based assays performed on diagnostic specimens will
allow for the identification of newer prognostic categories and potentially new
molecular targets for treatment of patients with sarcoma and other solid tumors.
- To determine whether serum levels of free IGF-I/II, total IGF-I and shed IGF-1R are of
significance in the outcome of patients with sarcoma and other solid tumors.
- To identify new treatment targets for therapy. Further testing of these potential
targets will be carried out in hopes of expediting translation of these findings to the
clinical setting.
Eligibility:
-All patients enrolled on the Phase II study SARC011/Roche NO21157 will be eligible for
enrollment.
Design:
- Unstained tumor tissue slides from samples sent for confirmatory diagnosis will be
forwarded for further analysis from Central Pathology Labs in New York or Leiden to
Roche Clinical Sample Operations (CSO). Tissue based assays to evaluate the status of
IGF-1R downstream pathway will be performed by Roche Central Lab (HistoGeneX) and NCI
Lab.
- Serum based assays of free serum IGF-I/II, total serum IGF-I and shed IGF-1R receptor
will be run using the samples obtained prior to the first dose of R1507 and at specified
times during treatment as described in Table 3.3. All serum samples will be shipped to
the Roche CSO and forwarded for analysis to the designated laboratories. Serum based
assays will be performed by Roche Central Lab (MicroCoat) and Roche Diagnostics
(Penzberg).
- INCLUSION CRITERIA:
All patients enrolled on the Phase II study SARC011/N021157 will be eligible for
enrollment.
Signed informed consent for this study according to institutional guidelines is required.
EXCLUSION CRITERIA:
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
